Summary
Twenty-nine patients with persistent, recurrent and/or metastatic squamous cell carcinoma of the head and neck were treated daily for five days at three-week intervals with topotecan 1.5 mg/m2. Four patients received prior chemotherapy, 23 prior surgery and 29 prior radiation therapy. Of the 29 eligible patients, 8 patients were not evaluable for response and were assumed to be non-responders. Of the remaining 21 évaluable patients, there were zero responses (0%, 95% confidence interval [0,.12]). The most common toxicities were myelosuppression, dyspnea and malaise/fatigue/lethargy. Topotecan has limited activity in advanced head and neck cancer with this dose and schedule.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kingsbury WD, Boehm JC, Jakas DR, Holden KG, Hecht SM, Gallagher G, Caranfa MJ, McCabe FL, Faucette LF, Johnson RK: Synthesis of water-soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem 34(1):98–107, 1991
Burris H, Kuhn J, Wall J, Eckardt J, Rodriguez G, Johnson R, Weiss G, Shaffer D, van Hoff D: Early clinical trials of topotecan, a new topoisomerase I inhibitor (abstract). Ann Oncol 3(Suppl 1):118, 1992
Rowinsky E, Grochow L, Hendricks C, Sartorius S, Ettinger D, McGuire W, Forastiere A, Hurowitz L, Easter V, Donehower R: Phase I and pharmacologic study ot topotecan (SKF 104864): a novel topoisomerase I inhibitor (abstract). Proc Am Soc Clin Oncol 10:A240, 1991
Wall J, Burris H, Rodriquez G, Brown T, Weiss G, Kuhn J, Brown J, Johnson R, Friedman C, Mann W, van Hoff D: Phase I trial of topotecan (SK&F 104864) in patients with refractory solid tumors (abstract). Proc Annu Meet Am Soc Clin Oncol 10:A261, 1991
Recondo G, Abbruzzese J, Newman B, Newman R, Kuhn J, van Hoff D, Garteiz D, Raber M: A phase I trial of topotecan (TOPO) administered by a 24-hour infusion (abstract). Proc Am Assoc Cancer Res 32:A1229, 1991
Robert F, Wheeler RH, Molthrop DC, Greene P, Chen S: Phase II study of topotecan in advanced head and neck cancer: identification of an active new agent (abstract). Proc Annu Meet Am Soc Clin Oncol 13:A905, 1994
Clavel M, Vermorken J, Cognetti F, deMulder P, Schornagel J, Verweij J, Kirkpatrick A, Dalesio O: Chemotherapy in recurrent and/or metastatic head and neck squamous cell carcinoma. Prognostic factors from 589 patients (pts) treated in three protocols (abstract). Proc Annu Meet Am Soc Clin Oncol 9:A692, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Smith, R.E., Lew, D., Rodriguez, G.I. et al. Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck. Invest New Drugs 14, 403–407 (1996). https://doi.org/10.1007/BF00180818
Issue Date:
DOI: https://doi.org/10.1007/BF00180818